Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Doxorubicin and Topotecan in Relapsed/Refractory NHL
NCT00006125Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Jul 2000
- Primary completion
- Aug 2006
- Modality
- DNA Intercalators/Alkylators
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of topotecan and doxorubicin in non-Hodgkin lymphoma (NHL), sponsored by Cancer and Leukemia Group B. Primary endpoint: Response Rate up to 5 years. Started Jul 2000; status: completed.
02
Drugs
topotecandoxorubicin
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00006125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006125.